In the past week, MED stock has gone down by -5.55%, with a monthly decline of -7.93% and a quarterly plunge of -21.83%. The volatility ratio for the week is 6.66%, and the volatility levels for the last 30 days are 4.12% for Medifast Inc The simple moving average for the past 20 days is -8.19% for MED’s stock, with a -25.79% simple moving average for the past 200 days.
Is It Worth Investing in Medifast Inc (NYSE: MED) Right Now?
Medifast Inc (NYSE: MED) has a higher price-to-earnings ratio of 75.53x compared to its average ratio, The 36-month beta value for MED is at 1.16. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for MED is 10.63M, and currently, shorts hold a 12.93% of that float. The average trading volume for MED on February 20, 2025 was 227.43K shares.
MED) stock’s latest price update
Medifast Inc (NYSE: MED)’s stock price has dropped by -11.41 in relation to previous closing price of 16.13. Nevertheless, the company has seen a loss of -5.55% in its stock price over the last five trading days. zacks.com reported 2025-02-19 that Medifast’s Q2 results show challenges related to weak customer acquisition. However, it is prioritizing efforts to enhance coach productivity in the near term.
Analysts’ Opinion of MED
Many brokerage firms have already submitted their reports for MED stocks, with DA Davidson repeating the rating for MED by listing it as a “Neutral.” The predicted price for MED in the upcoming period, according to DA Davidson is $17 based on the research report published on November 05, 2024 of the previous year 2024.
DA Davidson, on the other hand, stated in their research note that they expect to see MED reach a price target of $17.50, previously predicting the price at $25. The rating they have provided for MED stocks is “Underperform” according to the report published on June 05th, 2024.
Stephens gave a rating of “Equal-Weight” to MED, setting the target price at $82 in the report published on October 13th of the previous year.
MED Trading at -14.94% from the 50-Day Moving Average
After a stumble in the market that brought MED to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.36% of loss for the given period.
Volatility was left at 4.12%, however, over the last 30 days, the volatility rate increased by 6.66%, as shares sank -9.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.61% lower at present.
During the last 5 trading sessions, MED fell by -5.55%, which changed the moving average for the period of 200-days by -45.79% in comparison to the 20-day moving average, which settled at $15.56. In addition, Medifast Inc saw -18.90% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MED starting from SCHLACKMAN SCOTT, who sale 4,053 shares at the price of $39.44 back on Mar 08 ’24. After this action, SCHLACKMAN SCOTT now owns 7,785 shares of Medifast Inc, valued at $159,866 using the latest closing price.
Stock Fundamentals for MED
Current profitability levels for the company are sitting at:
- 0.0 for the present operating margin
- 0.74 for the gross margin
The net margin for Medifast Inc stands at 0.0. The total capital return value is set at 0.01. Equity return is now at value 1.02, with 0.68 for asset returns.
Based on Medifast Inc (MED), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 2.48. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is 2.35.
Currently, EBITDA for the company is 2.88 million with net debt to EBITDA at -8.18. When we switch over and look at the enterprise to sales, we see a ratio of 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.34.
Conclusion
In conclusion, Medifast Inc (MED) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
